iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Frances Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, to its Scientific Advisory Board (SAB).

Related Keywords

Germany ,Martinsried ,Bayern ,Wellington ,New Zealand General ,New Zealand ,United Kingdom ,German ,Athos Biopharma ,Philipp Beckhove ,Katja Arnold ,Nisit Khandelwal ,Frances Balkwill ,Shaun Brown ,Mc Services ,Professor At Barts Cancer Institute ,Queen Mary University Of London ,Cancer Research United Kingdom ,Clinical Trials Committee ,German Cancer Research Center ,Omx Therapeutics ,Cancer Biology ,Barts Cancer Institute ,Queen Mary University ,Scientific Advisory Board ,Senior Vice President Research ,Deputy Lead ,Tumour Microenvironment ,Blood Cancer United Kingdom ,Research Advisory Committee ,Prostate Cancer United ,Deputy Chair ,Professor Balkwill ,Wellington Partners ,Sofinnova Partners ,Resume ,Careers ,Omx Therapeutics Appoints Professor Frances Balkwill To The Scientific Advisory Board ,Iospace ,Advice ,